Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 4/20 | 0.51 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.46 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.46 |
| ▸ | PNMT | P11086 | 1/20 | 0.45 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | PGR | P06401 | 4/20 | 0.43 |
| ▸ | GRIA1 | P42261 | 2/20 | 0.43 |
| ▸ | CACNG8 | Q8WXS5 | 2/20 | 0.43 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 3/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | CMA1 | P23946 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15218966 | 0.81 | AHR (0.56) | AHRPDE3BPDE3APDK2EPHX2 | |
| SCHEMBL7650115 | 0.80 | AHR (0.58) | AHRPDE3BPDE3APDK2EPHX2 | |
| SCHEMBL7273904 | 0.76 | CA9 (0.53) | PNMTMAOB | |
| SCHEMBL14006308 | 0.70 | PNMT (0.44) | PNMT | |
| SCHEMBL5535534 | 0.68 | AHR (0.61) | AHRPDE3BPDE3APDK2EPHX2 | |
| SCHEMBL2468488 | 0.68 | AHR (0.61) | AHRPDE3BPDE3APDK2EPHX2 | |
| SCHEMBL1459491 | 0.68 | TDP2 (0.62) | AHRPDE3BPDE3APDK2EPHX2 | |
| SCHEMBL6431 | 0.68 | AHR (0.72) | AHRPDE3BPDE3APDK2EPHX2 | |
| SCHEMBL19391 | 0.68 | AHR (0.67) | AHRPDE3BPDE3APDK2EPHX2 | |
| SCHEMBL433708 | 0.68 | AHR (0.61) | AHRPDE3BPDE3APDK2EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2817310-B1 | 8-SUBSTITUTED 2-AMINO-[1,2,4]TRIAZOLO[1,5-A]PYRAZINES AS SYK TRYROSINE KINASE INHIBITORS AND GCN2 SERIN KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2018-03-21 | — | — | EP | disclosed |
| CN-104114557-B | 8-substituted 2-amino- [1,2,4] triazolo [1,5-a ] pyrazines as SYK tyrosine kinase inhibitors and GCN2 serine kinase inhibitors | 默克专利股份公司 | 2017-10-24 | — | — | CN | disclosed |
| EP-2609098-B1 | TRIAZOLOPYRAZINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2016-07-13 | — | — | EP | disclosed |
| CN-103068828-B | Triazolopyrazine Derivatives | MERCK PATENT GMBH (DE) | 2015-09-09 | — | — | CN | disclosed |
| US-9120804-B2 | 8-substituted 2-amino-[1,2,4] triazolo [1, 5-A] pyrazines as Syk tryrosine kinase inhibitors and GCN2 serin kinase inhibitors | MERCK PATENT GMBH (DE) | 2015-09-01 | — | — | US | disclosed |
| US-9023851-B2 | Triazolopyrazine derivatives | MERCK PATENT GMBH (DE) | 2015-05-05 | — | — | US | disclosed |
| US-20150025058-A1 | 8 - SUBSTITUTED 2 -AMINO - [1,2,4] TRIAZOLO [1, 5 -A] PYRAZINES AS SYK TRYROSINE KINASE INHIBITORS AND GCN2 SERIN KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2015-01-22 | — | — | US | disclosed |
| EP-2817310-A1 | 8 - SUBSTITUTED 2 -AMINO - [1,2,4]TRIAZOLO [1, 5 -A]PYRAZINES AS SYK TRYROSINE KINASE INHIBITORS AND GCN2 SERIN KINASE INHIBITORS | Merck Patent GmbH (DE) | 2014-12-31 | — | — | EP | disclosed |
| CN-104114557-A | 8-substituted 2-amino- [1,2,4] triazolo [1,5-a ] pyrazines as SYK tyrosine kinase inhibitors and GCN2 serine kinase inhibitors | MERCK PATENT GMBH | 2014-10-22 | — | — | CN | disclosed |
| US-20130225568-A1 | TRIAZOLOPYRAZINE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-08-29 | — | — | US | disclosed |
| WO-2013124026-A1 | 8 - SUBSTITUTED 2 -AMINO - [1,2,4] TRIAZOLO [1, 5 -A] PYRAZINES AS SYK TRYROSINE KINASE INHIBITORS AND GCN2 SERIN KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2013-08-29 | — | — | WO | disclosed |
| EP-2609098-A1 | TRIAZOLOPYRAZINE DERIVATIVES | Merck Patent GmbH (DE) | 2013-07-03 | — | — | EP | disclosed |
| CN-103068828-A | Triazolopyrazine derivatives | MERCK PATENT GMBH | 2013-04-24 | — | — | CN | disclosed |
| WO-2012025186-A1 | TRIAZOLOPYRAZINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2012-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150025058-A1 | 8 - SUBSTITUTED 2 -AMINO - [1,2,4] TRIAZOLO [1, 5 -A] PYRAZINES AS SYK TRYROSINE KINASE INHIBITORS AND GCN2 SERIN KINASE INHIBITORS | SYK, EIF2AK4, BTK | AHR 3362/4885PDE3B 2705/4885PDE3A 2474/4885 |
| US-20130225568-A1 | TRIAZOLOPYRAZINE DERIVATIVES | SYK, IRAK1, ZAP70 | AHR 1961/4885PDE3B 1032/4885PDE3A 579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.